RhumbLine Advisers’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-53,509
| Closed | -$2.02M | – | 3208 |
|
|
2021
Q1 | $2.02M | Sell |
53,509
-803
| -1% | -$20K | ﹤0.01% | 1909 |
|
|
2020
Q4 | $924K | Buy |
54,312
+9,853
| +22% | +$123K | ﹤0.01% | 2169 |
|
|
2020
Q3 | $209K | Sell |
44,459
-7,071
| -14% | -$35.9K | ﹤0.01% | 2672 |
|
|
2020
Q2 | $314K | Sell |
51,530
-7,875
| -13% | -$32.4K | ﹤0.01% | 2557 |
|
|
2020
Q1 | $135K | Buy |
59,405
+1,972
| +3% | +$8.37K | ﹤0.01% | 2708 |
|
|
2019
Q4 | $264K | Buy |
57,433
+243
| +0.4% | +$962 | ﹤0.01% | 2652 |
|
|
2019
Q3 | $222K | Buy |
57,190
+4,657
| +9% | +$25.6K | ﹤0.01% | 2712 |
|
|
2019
Q2 | $317K | Buy |
52,533
+4,189
| +9% | +$40.1K | ﹤0.01% | 2584 |
|
|
2019
Q1 | $648K | Sell |
48,344
-296
| -0.6% | -$3.38K | ﹤0.01% | 2212 |
|
|
2018
Q4 | $452K | Buy |
48,640
+14,412
| +42% | +$171K | ﹤0.01% | 2341 |
|
|
2018
Q3 | $476K | Buy |
34,228
+446
| +1% | +$6.63K | ﹤0.01% | 2296 |
|
|
2018
Q2 | $534K | Buy |
33,782
+1,415
| +4% | +$24.7K | ﹤0.01% | 2280 |
|
|
2018
Q1 | $556K | Buy |
32,367
+2,875
| +10% | +$56.1K | ﹤0.01% | 2172 |
|
|
2017
Q4 | $646K | Sell |
29,492
-5,180
| -15% | -$167K | ﹤0.01% | 2135 |
|
|
2017
Q3 | $1.42M | Buy |
34,672
+390
| +1% | +$12.2K | ﹤0.01% | 1809 |
|
|
2017
Q2 | $1.03M | Buy |
34,282
+484
| +1% | +$15.1K | ﹤0.01% | 1941 |
|
|
2017
Q1 | $1.22M | Buy |
33,798
+970
| +3% | +$42.8K | ﹤0.01% | 1823 |
|
|
2016
Q4 | $1.65M | Buy |
32,828
+338
| +1% | +$17.8K | ﹤0.01% | 1565 |
|
|
2016
Q3 | $1.71M | Buy |
32,490
+915
| +3% | +$43.7K | ﹤0.01% | 1517 |
|
|
2016
Q2 | $1.31M | Buy |
31,575
+8,676
| +38% | +$377K | ﹤0.01% | 1620 |
|
|
2016
Q1 | $930K | Buy |
22,899
+1,040
| +5% | +$35.7K | ﹤0.01% | 1837 |
|
|
2015
Q4 | $907K | Buy |
21,859
+2,600
| +14% | +$87.2K | ﹤0.01% | 1874 |
|
|
2015
Q3 | $296K | Buy |
19,259
+719
| +4% | +$15.5K | ﹤0.01% | 2550 |
|
|
2015
Q2 | $461K | Sell |
18,540
-115
| -0.6% | -$2.56K | ﹤0.01% | 2387 |
|
|
2015
Q1 | $426K | Buy |
18,655
+4,650
| +33% | +$117K | ﹤0.01% | 2390 |
|
|
2014
Q4 | $378K | Buy |
14,005
+1,185
| +9% | +$20.4K | ﹤0.01% | 2445 |
|
|
2014
Q3 | $150K | Hold |
12,820
| – | – | ﹤0.01% | 2853 |
|
|
2014
Q2 | $199K | Buy |
+12,820
| New | +$184K | ﹤0.01% | 2843 |
|
RhumbLine Advisers's FPRX Position: Q2 2021 in Review
RhumbLine Advisers sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 53,509 shares — an estimated $2.02M sold.
RhumbLine Advisers first reported a position in FPRX in Q2 2014 and held it in 28 quarters. The position peaked at $2.02M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- RhumbLine Advisers reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- RhumbLine Advisers sold 53,509 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $2.02M.
- RhumbLine Advisers first reported a position in Five Prime Therapeutics, Inc. in Q2 2014 and held it in 28 quarters.
- RhumbLine Advisers's Five Prime Therapeutics, Inc. position peaked at $2.02M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.